Enrolling by invitationEarly Phase 1NCT07520214

Clinical Study on the Safety and Immunogenicity of Specific Cancer Vaccines in Preventing Recurrence of Glioblastoma

Studying Infective dermatitis associated with HTLV-1

Last synced from ClinicalTrials.gov May 11, 2026

ℹ

Clinical trial records are synced from ClinicalTrials.gov through automated extraction.

Report missing data

Key facts

Sponsor: Beijing Neurosurgical Institute
Principal Investigator: Fusheng Liu, MD,PhD
Beijing Tiantan Hospital
Intervention: mRNA vaccine: GV-907、GV-108(biological)
Enrollment: 9 target
Eligibility: 18 years · All sexes
Timeline: 2025 – 2027

Study locations (1)

Beijing Tiantan Hospital, Beijing, Beijing Municipality, China

Primary source

Recruitment status, site addresses, contacts, and full eligibility criteria can change between syncs. Always verify with the trial team before planning travel or treatment.

Open NCT07520214 on ClinicalTrials.gov

Other trials for Infective dermatitis associated with HTLV-1

Additional recruiting or active studies for the same condition.

RECRUITINGNCT07547163
Patient Voice in the Treatment of Low-grade Gliomas: Use of Patient-reported Outcomes, Vorasidenib and Radiotherapy Compared
Fondazione I.R.C.C.S. Istituto Neurologico Carlo Besta

See all trials for Infective dermatitis associated with HTLV-1 →

← Back to all trials